Is Dianthus Therapeutics Inc. (DNTH) overvalued? · rev $6.2M
Dianthus Therapeutics Inc. (DNTH) is a biotechnology company listed on US.
This page asks whether Dianthus Therapeutics Inc. (DNTH) looks expensive on cached numbers — not a short thesis.
Latest reported DNTH revenue for 2024-12-31 was $6.2M. Net income was -$85.0M. Revenue was up 120.6% from 2023-12-31 to 2024-12-31. DNTH currently screens at market cap $4.40B.
DNTH currently screens at market cap $4.40B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next DNTH 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the DNTH stock page for the full model, not this heading.
Not investment advice.